NYSE:Global Blood Therapeutics, Inc.
График котировок Global Blood Therapeutics, Inc.
График GBT предоставлен TradingView
Добавить в список сравнения
Добавить в список отслеживания
Добавить в портфель
Основные параметры
P/S | 31.2 |
---|---|
P/BV | 5.85 |
EV/EBITDA | -8.03 |
EBITDA | -0.29 |
Цена ао | 46.94 |
Основные владельцы
Institutions | Объем | Доля, % |
---|---|---|
First Trust Portfolios L.P. | 45691 | 0.07 |
Hennion & Walsh, Inc | 500 | 0 |
Janus Capital Management LLC | 5996305 | 9.7 |
Logos Global Management LP | 850000 | 1.38 |
Nicholas Investment Partners | 11983 | 0.02 |
Asymmetry Capital Management, L.P. | 155232 | 0.25 |
CT Mason | 124749 | 0.2 |
Security Investors, LLC | 80430 | 0.13 |
Fernwood Investment Management, LLC | 187477 | 0.3 |
Perceptive Advisors LLC | 5800996 | 9.39 |
First Midwest Bank | 14582 | 0.02 |
John Hancock Investment Management LLC | 221913 | 0.36 |
Botty Investors LLC | 217510 | 0.35 |
Fidelity Management & Research Company LLC | 3717701 | 6.02 |
Pharmakon Advisors L.P. | 653414 | 1.06 |
BNP Paribas Asset Management Luxembourg | 280239 | 0.45 |
AQA Capital Limited | 5000 | 0.01 |
Fidelity Investments | 381839 | 0.62 |
Great Point Partners LLC | 655676 | 1.06 |
Hennion & Walsh, Inc | 500 | 0 |
Munder Lee Investments Ltd | 20405 | 0.03 |
Fidelity Management & Research Company LLC | 3431107 | 5.55 |
Fidelity Investments Canada ULC | 25678 | 0.04 |
Похожие компании
Описание Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.